Benzylthiouracil

Benzylthiouracil

Systematic (IUPAC) name
1-(1-cyclohexa-2,4-dienylmethyl)-7-thia- 3,5-diazabicyclo[4.1.0]hepta-3,5-dien-2-one
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
Pharmacokinetic data
Excretion	Renal
Identifiers
CAS Number	6336-50-1
ATC code	H03BA03 (WHO)
PubChem	CID 685814
ChemSpider	597542
UNII	PZ35LUM333
ChEMBL	CHEMBL1491306
Chemical data
Formula	C11H10N2OS
Molar mass	218.276 g/mol
SMILES S=C1N/C(=C\C(=O)N1)Cc2ccccc2
InChI InChI=1S/C11H10N2OS/c14-10-7-9(12-11(15)13-10)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H2,12,13,14,15) Key:PNXBXCRWXNESOV-UHFFFAOYSA-N
(verify)

Benzylthiouracil (BTU) is an antithyroid preparation. It is a thioamide, closely related to propylthiouracil.

Adverse effects

Benzylthiouracil has been associated with severe adverse effects, notably vasculitis and subsequent ANCA-positive glomerulonephritis, as well as isolated reports of lung damage.^[1][2][3][4]

References

1. Tieulie N, Huong DL, Andreu M; et al. (2002). "[ANCA associated glomerulonephritis related to benzylthiouracil]". Rev Med Interne (in French) 23 (10): 853–6. doi:10.1016/S0248-8663(02)00694-X. PMID 12428489.
2. Kaaroud H, Khiari K, Ben Moussa F, Barbouch S, Boussema E, Ben Maïz H (2002). "[Vasculitis with renal and pulmonary involvement in a patient receiving benzylthiouracil for Graves disease]". Rev Med Interne (in French) 23 (10): 857–61. doi:10.1016/S0248-8663(02)00704-X. PMID 12428490.
3. Braham A, Houman MH, Rais L, Ben Gborbel I, Lamloum M, Miled M (2004). "[Benzylthiouracil induced ANCA-positive vasculitis]". Presse Médicale (in French) 33 (19 Pt 1): 1331–3. doi:10.1016/S0755-4982(04)98919-1. PMID 15615240.
4. Thabet F, Sghiri R, Tabarki B, Ghedira I, Yacoub M, Essoussi AS (2006). "ANCA-associated diffuse alveolar hemorrhage due to benzylthiouracil". Eur J Pediatr 165 (7): 435–6. doi:10.1007/s00431-005-0053-4. PMID 16622664.